Retatrutide (LY3437943) is a once-weekly injectable triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, with a molecular weight of approximately 5052.9 g/mol. Developed by Eli Lilly, it represents the frontier of incretin-based metabolic research, with Phase 2 clinical trial data showing differentiated outcomes compared to single and dual agonists.
The addition of glucagon receptor agonism to the GLP-1/GIP dual mechanism creates a tripartite action on energy homeostasis: incretin-mediated insulin secretion, appetite regulation, and direct stimulation of hepatic fatty acid oxidation and thermogenesis. For researchers investigating the comparative pharmacology of incretin receptor systems, retatrutide enables the study of all three pathways in a single compound.
Each Etched Research vial contains 10mg of lyophilized powder, purity-verified at ≥99% via HPLC and mass spectrometry. Batch-specific Certificate of Analysis included.
Specifications:
– Molecular Weight: ~5052.9 g/mol
– Purity: ≥99% (HPLC + Mass Spectrometry)
– Form: Lyophilized powder
– Storage: -20°C (lyophilized); 4°C once reconstituted, use within 30 days
FOR IN VITRO RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION, INGESTION, OR ANY IN VIVO USE.
- What it is: A lab-made molecule (also called LY3437943) that switches on three hormone receptors at once: GLP-1, GIP, and glucagon.
- Researchers have studied it for: Body weight in obesity, blood sugar (HbA1c) in type 2 diabetes, and liver fat.
- Evidence level: Phase 2 human trials exist, meaning mid-stage.
- The short version: Retatrutide is one of the newest metabolic compounds, and it already has real phase 2 human data. Researchers recorded large drops in body weight, blood sugar, and liver fat within specific patient groups over under a year. It is still investigational with no approval, the trials logged mostly gut-related side effects, and none of this is a safety conclusion.
Reviews
There are no reviews yet.